Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Moodys
Farmers Insurance
Teva
Daiichi Sankyo
Deloitte
Harvard Business School
QuintilesIMS

Generated: May 21, 2018

DrugPatentWatch Database Preview

Taro Company Profile

« Back to Dashboard

What is the competitive landscape for TARO, and what generic alternatives to TARO drugs are available?

TARO has two hundred and eleven approved drugs.

There are ten US patents protecting TARO drugs. There are three tentative approvals on TARO drugs.

There are sixty-two patent family members on TARO drugs in seventeen countries and eighty-five supplementary protection certificates in twelve countries.

Summary for Taro
International Patents:62
US Patents:10
Tradenames:111
Ingredients:94
NDAs:211
Patent Litigation for Taro: See patent lawsuits for Taro
PTAB Cases with Taro as petitioner: See PTAB cases with Taro as petitioner

Drugs and US Patents for Taro

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro TOPICORT desoximetasone OINTMENT;TOPICAL 018763-001 Sep 30, 1983 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Taro TOPICORT desoximetasone GEL;TOPICAL 018586-001 Mar 29, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Taro Pharm AMIODARONE HYDROCHLORIDE amiodarone hydrochloride TABLET;ORAL 076362-002 Dec 2, 2003 RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Taro FLUOCINONIDE fluocinonide CREAM;TOPICAL 071500-001 Jun 10, 1987 AB1 RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Taro

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Taro TOPICORT desoximetasone SPRAY;TOPICAL 204141-001 Apr 11, 2013 5,990,100 ➤ Try a Free Trial
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-002 Jan 17, 2008 5,881,926 ➤ Try a Free Trial
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-001 Jan 17, 2008 6,102,254 ➤ Try a Free Trial
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-001 Jan 17, 2008 5,881,926 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for TARO drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Lotion 0.5% ➤ Subscribe 2011-03-16
➤ Subscribe Topical Spray 0.25% ➤ Subscribe 2013-12-18
Premature patent expirations for TARO

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Try a Free Trial ➤ Try a Free Trial

Non-Orange Book US Patents for Taro

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,957,238 Process for preparing malathion for pharmaceutical use ➤ Try a Free Trial
5,886,038 Composition and method for treatment of psoriasis ➤ Try a Free Trial
8,536,155 Process for preparing malathion for pharmaceutical use ➤ Try a Free Trial
8,039,657 Process for preparing malathion for pharmaceutical use ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Taro Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB97/064 United Kingdom ➤ Try a Free Trial PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410
C/GB07/011 United Kingdom ➤ Try a Free Trial PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
90062-5 Sweden ➤ Try a Free Trial PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
C/GB05/030 United Kingdom ➤ Try a Free Trial PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
McKesson
QuintilesIMS
Teva
Chinese Patent Office
Medtronic
US Army
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.